Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits

Autores
D'Anunzio, Verónica; Donato, Pablo Martín; Erni, Lukas; Miksztowicz, Verónica Julieta; Buchholz, Bruno; Lorenzo Carrión, María Cristina; Schreier, Laura Ester; Wigdorovitz de Wikinski, Regina Luisa; Gelpi, Ricardo Jorge; Berg, Gabriela Alicia; Basso, Nidia
Año de publicación
2009
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
There is evidence that statin treatment before ischemia protects myocardium from ischemia/reperfusion injury. Objective: to determine whether rosuvastatin administered during reperfusion modifies infarct size and the recovery of postischemic ventricular dysfunction in normo and hypercholesterolemic rabbit. Additionally, we also evaluated the role of MMP-2 activation. Langendorff-perfused rabbit hearts were subjected to 30 minutes of ischemia and 120 minutes of reperfusion. In group 2, we added rosuvastatin after 30 minutes of ischemia and from the beginning of reperfusion. In group 3, an MMP inhibitor (doxycycline) was administered during the first 2 min of reperfusion. Finally, we repeated these groups but in hypercholesterolemic rabbits (Groups 4, 5 and 6). The infarct size was 16.6±2.6% in group 1 and 25.6±2.7% in group 4. Rosuvastatin reduced infarct size to 4.5±1.1% and 5.5±1.6% in groups 2 and 5, respectively (p<0.05). Rosuvastatin significantly decreased MMP-2 activity during reperfusion and doxycycline induced an inhibition of MMP-2 activity and a reduction of infarct size in normo (4.9±0.9 %) and hypercholesterolemic animals (8.3±1.6%) (p<0.05). Rosuvastatin reduces infarct size and attenuates MMP-2 activity. These data and the correlation between MMP-2 and infarct size suggests that MMP-2 plays an important role in the mechanisms of cardioprotection afforded by rosuvastatin.
Fil: D'Anunzio, Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Donato, Pablo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Erni, Lukas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Miksztowicz, Verónica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Buchholz, Bruno. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Lorenzo Carrión, María Cristina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Wigdorovitz de Wikinski, Regina Luisa. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina
Fil: Gelpi, Ricardo Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina
Fil: Basso, Nidia. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Materia
MYOCARDIAL INFARCTION
STATINS
MATRIX METALLOPROTEINASES
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/103295
Acceder
id CONICETDig_b65688cc1fcf03dc7683f2b4d8e42fa5
oai_identifier_str oai:ri.conicet.gov.ar:11336/103295
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic RabbitsD'Anunzio, VerónicaDonato, Pablo MartínErni, LukasMiksztowicz, Verónica JulietaBuchholz, BrunoLorenzo Carrión, María CristinaSchreier, Laura EsterWigdorovitz de Wikinski, Regina LuisaGelpi, Ricardo JorgeBerg, Gabriela AliciaBasso, NidiaMYOCARDIAL INFARCTIONSTATINSMATRIX METALLOPROTEINASEShttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3There is evidence that statin treatment before ischemia protects myocardium from ischemia/reperfusion injury. Objective: to determine whether rosuvastatin administered during reperfusion modifies infarct size and the recovery of postischemic ventricular dysfunction in normo and hypercholesterolemic rabbit. Additionally, we also evaluated the role of MMP-2 activation. Langendorff-perfused rabbit hearts were subjected to 30 minutes of ischemia and 120 minutes of reperfusion. In group 2, we added rosuvastatin after 30 minutes of ischemia and from the beginning of reperfusion. In group 3, an MMP inhibitor (doxycycline) was administered during the first 2 min of reperfusion. Finally, we repeated these groups but in hypercholesterolemic rabbits (Groups 4, 5 and 6). The infarct size was 16.6±2.6% in group 1 and 25.6±2.7% in group 4. Rosuvastatin reduced infarct size to 4.5±1.1% and 5.5±1.6% in groups 2 and 5, respectively (p<0.05). Rosuvastatin significantly decreased MMP-2 activity during reperfusion and doxycycline induced an inhibition of MMP-2 activity and a reduction of infarct size in normo (4.9±0.9 %) and hypercholesterolemic animals (8.3±1.6%) (p<0.05). Rosuvastatin reduces infarct size and attenuates MMP-2 activity. These data and the correlation between MMP-2 and infarct size suggests that MMP-2 plays an important role in the mechanisms of cardioprotection afforded by rosuvastatin.Fil: D'Anunzio, Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; ArgentinaFil: Donato, Pablo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; ArgentinaFil: Erni, Lukas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; ArgentinaFil: Miksztowicz, Verónica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Buchholz, Bruno. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Lorenzo Carrión, María Cristina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; ArgentinaFil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaFil: Wigdorovitz de Wikinski, Regina Luisa. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; ArgentinaFil: Gelpi, Ricardo Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; ArgentinaFil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; ArgentinaFil: Basso, Nidia. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaLippincott Williams2009-02info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/103295D'Anunzio, Verónica; Donato, Pablo Martín; Erni, Lukas; Miksztowicz, Verónica Julieta; Buchholz, Bruno; et al.; Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits; Lippincott Williams; Journal Of Cardiovascular Pharmacology; 53; 2; 2-2009; 137-1440160-2446CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.lww.com/cardiovascularpharm/Abstract/2009/02000/Rosuvastatin_Given_During_Reperfusion_Decreases.8.aspxinfo:eu-repo/semantics/altIdentifier/doi/10.1097/FJC.0b013e318197c5e9info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:54:52Zoai:ri.conicet.gov.ar:11336/103295instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:54:52.556CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
title Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
spellingShingle Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
D'Anunzio, Verónica
MYOCARDIAL INFARCTION
STATINS
MATRIX METALLOPROTEINASES
title_short Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
title_full Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
title_fullStr Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
title_full_unstemmed Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
title_sort Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits
dc.creator.none.fl_str_mv D'Anunzio, Verónica
Donato, Pablo Martín
Erni, Lukas
Miksztowicz, Verónica Julieta
Buchholz, Bruno
Lorenzo Carrión, María Cristina
Schreier, Laura Ester
Wigdorovitz de Wikinski, Regina Luisa
Gelpi, Ricardo Jorge
Berg, Gabriela Alicia
Basso, Nidia
author D'Anunzio, Verónica
author_facet D'Anunzio, Verónica
Donato, Pablo Martín
Erni, Lukas
Miksztowicz, Verónica Julieta
Buchholz, Bruno
Lorenzo Carrión, María Cristina
Schreier, Laura Ester
Wigdorovitz de Wikinski, Regina Luisa
Gelpi, Ricardo Jorge
Berg, Gabriela Alicia
Basso, Nidia
author_role author
author2 Donato, Pablo Martín
Erni, Lukas
Miksztowicz, Verónica Julieta
Buchholz, Bruno
Lorenzo Carrión, María Cristina
Schreier, Laura Ester
Wigdorovitz de Wikinski, Regina Luisa
Gelpi, Ricardo Jorge
Berg, Gabriela Alicia
Basso, Nidia
author2_role author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv MYOCARDIAL INFARCTION
STATINS
MATRIX METALLOPROTEINASES
topic MYOCARDIAL INFARCTION
STATINS
MATRIX METALLOPROTEINASES
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv There is evidence that statin treatment before ischemia protects myocardium from ischemia/reperfusion injury. Objective: to determine whether rosuvastatin administered during reperfusion modifies infarct size and the recovery of postischemic ventricular dysfunction in normo and hypercholesterolemic rabbit. Additionally, we also evaluated the role of MMP-2 activation. Langendorff-perfused rabbit hearts were subjected to 30 minutes of ischemia and 120 minutes of reperfusion. In group 2, we added rosuvastatin after 30 minutes of ischemia and from the beginning of reperfusion. In group 3, an MMP inhibitor (doxycycline) was administered during the first 2 min of reperfusion. Finally, we repeated these groups but in hypercholesterolemic rabbits (Groups 4, 5 and 6). The infarct size was 16.6±2.6% in group 1 and 25.6±2.7% in group 4. Rosuvastatin reduced infarct size to 4.5±1.1% and 5.5±1.6% in groups 2 and 5, respectively (p<0.05). Rosuvastatin significantly decreased MMP-2 activity during reperfusion and doxycycline induced an inhibition of MMP-2 activity and a reduction of infarct size in normo (4.9±0.9 %) and hypercholesterolemic animals (8.3±1.6%) (p<0.05). Rosuvastatin reduces infarct size and attenuates MMP-2 activity. These data and the correlation between MMP-2 and infarct size suggests that MMP-2 plays an important role in the mechanisms of cardioprotection afforded by rosuvastatin.
Fil: D'Anunzio, Verónica. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Donato, Pablo Martín. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Erni, Lukas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Miksztowicz, Verónica Julieta. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Buchholz, Bruno. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Lorenzo Carrión, María Cristina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Schreier, Laura Ester. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Fil: Wigdorovitz de Wikinski, Regina Luisa. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina
Fil: Gelpi, Ricardo Jorge. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina
Fil: Berg, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina. Universidad de Buenos Aires. Facultad de Farmacia y Bioquímica. Departamento de Bioquímica Clínica; Argentina
Fil: Basso, Nidia. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Fisiopatología Cardiovascular; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
description There is evidence that statin treatment before ischemia protects myocardium from ischemia/reperfusion injury. Objective: to determine whether rosuvastatin administered during reperfusion modifies infarct size and the recovery of postischemic ventricular dysfunction in normo and hypercholesterolemic rabbit. Additionally, we also evaluated the role of MMP-2 activation. Langendorff-perfused rabbit hearts were subjected to 30 minutes of ischemia and 120 minutes of reperfusion. In group 2, we added rosuvastatin after 30 minutes of ischemia and from the beginning of reperfusion. In group 3, an MMP inhibitor (doxycycline) was administered during the first 2 min of reperfusion. Finally, we repeated these groups but in hypercholesterolemic rabbits (Groups 4, 5 and 6). The infarct size was 16.6±2.6% in group 1 and 25.6±2.7% in group 4. Rosuvastatin reduced infarct size to 4.5±1.1% and 5.5±1.6% in groups 2 and 5, respectively (p<0.05). Rosuvastatin significantly decreased MMP-2 activity during reperfusion and doxycycline induced an inhibition of MMP-2 activity and a reduction of infarct size in normo (4.9±0.9 %) and hypercholesterolemic animals (8.3±1.6%) (p<0.05). Rosuvastatin reduces infarct size and attenuates MMP-2 activity. These data and the correlation between MMP-2 and infarct size suggests that MMP-2 plays an important role in the mechanisms of cardioprotection afforded by rosuvastatin.
publishDate 2009
dc.date.none.fl_str_mv 2009-02
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/103295
D'Anunzio, Verónica; Donato, Pablo Martín; Erni, Lukas; Miksztowicz, Verónica Julieta; Buchholz, Bruno; et al.; Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits; Lippincott Williams; Journal Of Cardiovascular Pharmacology; 53; 2; 2-2009; 137-144
0160-2446
CONICET Digital
CONICET
url http://hdl.handle.net/11336/103295
identifier_str_mv D'Anunzio, Verónica; Donato, Pablo Martín; Erni, Lukas; Miksztowicz, Verónica Julieta; Buchholz, Bruno; et al.; Rosuvastatin Given During Reperfusion Decreases Infarct Size and Inhibits Matrix Metalloproteinase-2 Activity in Normocholesterolemic and Hypercholesterolemic Rabbits; Lippincott Williams; Journal Of Cardiovascular Pharmacology; 53; 2; 2-2009; 137-144
0160-2446
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://journals.lww.com/cardiovascularpharm/Abstract/2009/02000/Rosuvastatin_Given_During_Reperfusion_Decreases.8.aspx
info:eu-repo/semantics/altIdentifier/doi/10.1097/FJC.0b013e318197c5e9
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Lippincott Williams
publisher.none.fl_str_mv Lippincott Williams
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269311984467968
score 13.13397

Publicaciones similares